Ezetimibe — patient guide

This page covers ezetimibe — Ezetrol and generics — and the combination tablets that pair it with a statin (Atozet, Vytorin, Inegy, Goltor). If your tablet name is one of those, this is your page.

---

Find your medicine

Generic name	Common brand names	Strengths	How often
Ezetimibe	Ezetrol, generics	10 mg	Once daily
Atorvastatin + ezetimibe	Atozet	Atorvastatin 10 / 20 / 40 / 80 mg + ezetimibe 10 mg	Once daily
Simvastatin + ezetimibe	Vytorin, Inegy, Goltor	Simvastatin 10 / 20 / 40 / 80 mg + ezetimibe 10 mg	Once nightly

Combination-tablet note. The simvastatin-ezetimibe combination has been sold in Australia under several brand names (Vytorin, Inegy, Goltor) and the brand on the shelf has shifted over time. Same drug, different labels. Confirm what your pharmacist has dispensed.

Adjacent options on the lipid-lowering ladder. If a statin plus ezetimibe is not enough, or not tolerated, the usual next steps are:

• Bempedoic acid (Nilemdo) — different mechanism, no muscle-symptom signal. AU availability has lagged the US and UK; confirm current ARTG / PBS status.
• PCSK9 inhibitors — Praluent (alirocumab) and Repatha (evolocumab). Subcutaneous injections, fortnightly or monthly. PBS Streamlined Authority for very-high-cardiovascular-risk patients on a maximally-tolerated statin plus ezetimibe. Specialist-initiated.

---

What it treats

Ezetimibe is prescribed for one underlying job — lowering LDL cholesterol — across a few different clinical settings:

• Add-on to a statin when LDL is not at target. The most common reason. The statin lowers what the liver makes; ezetimibe lowers what the gut absorbs. Effects are additive.
• Monotherapy when a statin is not tolerated. After trialling dose reduction and at least one switch within the statin class, ezetimibe on its own is a reasonable step.
• Familial hypercholesterolaemia. Usually as part of a stepwise approach with a statin, sometimes followed by a PCSK9 inhibitor.
• Cardiovascular event reduction after a recent acute coronary syndrome — supported by IMPROVE-IT (NEJM 2015).
• Cardiovascular event reduction in chronic kidney disease — supported by SHARP (Lancet 2011).

The doctor who prescribed it will know which of these applies.

---

The basics

1. Take it once a day, at the same time. No food restrictions. The 10 mg dose is the only dose — no titration.
2. If you are on a bile acid sequestrant (colestyramine, colestipol), take ezetimibe at least 2 hours before or 4 hours after — otherwise the sequestrant blocks ezetimibe absorption.
3. Go to ED if your lips, tongue, throat, or face suddenly swell, or if you develop severe muscle pain with dark or tea-coloured urine on the statin combination. Rare, but serious. Stop the medicine on the way.
4. Do not stop on your own. If something feels wrong, message the prescribing GP — most problems can be sorted without stopping.

Everything else — side effects, the blood tests involved, the integrative angle — is below.

---

What to expect in the first month

Week 1

• No felt change, usually. Cholesterol medicines do not have a noticeable day-to-day effect.
• Mild gastrointestinal upset can show up early — loose stools, a bit of cramping, more wind. Often settles with continued use.

Weeks 2-4

• The LDL-lowering effect builds and is essentially at steady state by 2 weeks.
• A repeat lipid panel is usually taken at around 4-8 weeks to see what the drop looks like, and to compare against the target LDL.
• If a statin is being taken alongside, a liver function test and CK (a muscle enzyme) are reasonable at the same time.

---

Tap any section below to expand the detail.

How does it work?

Ezetimibe blocks a transporter called NPC1L1 sitting on the brush border of the small bowel. NPC1L1 is the door through which cholesterol — from food and from bile — crosses into the bloodstream. Blocking it reduces how much cholesterol gets absorbed. The liver responds by pulling more LDL out of the blood to make up the shortfall, and circulating LDL drops.

The mechanism is independent of the statin pathway. Statins block HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis inside the liver. Ezetimibe blocks absorption at the gut wall. The two drugs operate in different places, which is why the effects add up when they are combined.

On the numbers: as monotherapy, ezetimibe lowers LDL by roughly 15-22%. Added to a statin, it lowers LDL by a further 15-20% on top of the statin effect. Single 10 mg dose — no titration, no upward step.

Side effects in detail

Common (usually mild)

• Gastrointestinal upset. Diarrhoea, abdominal pain, flatulence. Usually mild, often improves with continued use.
• Headache or fatigue in the early weeks, usually settling.

Uncommon

• Muscle aches. Rare with ezetimibe alone. When ezetimibe is taken with a statin (either as Atozet or Vytorin / Inegy / Goltor, or as separate tablets), the statin is almost always the dominant contributor to muscle symptoms. The clinical move is the same as for any statin-associated muscle symptom: check CK, check vitamin D, trial a pause-and-rechallenge, a dose reduction, or a switch within the statin class.
• Liver enzyme rise. Transaminase elevations are uncommon with ezetimibe alone and slightly more frequent when ezetimibe is combined with a statin than with the statin alone — pooled trial data show a small additive signal. Persistent elevations greater than 3x the upper limit of normal warrant pause and review.
• Mild rash.

Rare but serious — go to ED

• Rhabdomyolysis. Severe muscle pain plus dark / tea-coloured urine plus a markedly raised CK. Rare overall; the signal is driven almost entirely by the partner statin in combination tablets, not by ezetimibe itself. Stop the medicine and go to ED.
• Angioedema / hypersensitivity. Sudden swelling of face, lips, tongue, or throat. Rare. Stop the medicine and get to ED.
• Gallstones. A modest post-marketing signal, particularly when ezetimibe is combined with a fibrate (where the gallstone risk of the fibrate is the dominant contributor). New biliary-type pain — right upper abdomen, after fatty meals — warrants investigation.
• Pancreatitis and thrombocytopenia. Both rare; mentioned in the TGA Product Information. Unexplained bruising, prolonged bleeding, or severe abdominal pain warrant review.

Drugs, food, and alcohol

Tell the GP or pharmacist before combining with:

• Ciclosporin. Ezetimibe blood levels rise significantly when ciclosporin is on board, and ciclosporin levels can also rise. Specialist input; ciclosporin levels need monitoring.
• Bile acid sequestrants — colestyramine (Questran) and colestipol. They bind ezetimibe in the gut and block its absorption. Take ezetimibe at least 2 hours before, or 4 hours after, the sequestrant.
• Fibrates — gemfibrozil and fenofibrate. There is a modest additional gallstone signal when combined with ezetimibe; gemfibrozil also raises ezetimibe levels. Fenofibrate is the preferred fibrate if combination is needed, on specialist advice.
• Warfarin. A small rise in INR has been reported after starting ezetimibe. Have the INR checked in the first 1-2 weeks.
• Statin-side interactions on the combination tablets. If the tablet is Atozet (atorvastatin + ezetimibe) or Vytorin / Inegy / Goltor (simvastatin + ezetimibe), the statin half of the tablet carries its own interaction profile — particularly the CYP3A4 ones for atorvastatin and simvastatin (macrolide antibiotics like clarithromycin and erythromycin; azole antifungals; amiodarone; diltiazem and verapamil; ciclosporin; HIV and HCV antivirals; high-intake grapefruit juice). The simvastatin combination is more restrictive — moderate-to-strong CYP3A4 inhibitors generally need a switch to the atorvastatin combination, or to a non-CYP3A4-metabolised statin (rosuvastatin, pravastatin, fluvastatin, pitavastatin) plus separate ezetimibe.
• Red yeast rice supplements. Contain monacolin K (chemically identical to lovastatin) and behave like a low-dose statin. Do not combine with a prescribed statin and ezetimibe — additive statin effect, additive transaminitis and muscle-symptom signal, additive interaction profile.

Food. No specific food restrictions for ezetimibe. Grapefruit caveat applies only if the tablet contains atorvastatin or simvastatin.

Alcohol. Light to moderate intake is acceptable. Keep within AU NHMRC guidelines (no more than 10 standard drinks per week and no more than 4 on any one day) — particularly relevant for the statin combinations because the hepatic safety signal is additive.

Generic substitution at the pharmacy. Generic ezetimibe is bioequivalent to Ezetrol and works the same. If the pharmacist offers a cheaper generic, that is fine.

Monitoring — what blood tests and when

• Lipid panel at 4-8 weeks after starting (or after a dose change of the partner statin) — to see what the LDL drop looks like and compare against the target.
• Liver function test (ALT, AST) and CK (a muscle enzyme) at the same time if a statin is being taken alongside. Repeat if symptoms warrant.
• Then annually with routine review, unless something changes.
• Message the GP if you: start a new medicine (including over-the-counter or supplements), develop persistent gastrointestinal symptoms, develop muscle aches on the statin combination, or develop biliary-type abdominal pain.

Stopping or pausing

• Do not stop without talking to the prescribing GP first.
• If side effects are the problem, the usual move is to investigate the cause — particularly if a statin is on board, because the statin is more often the contributor than ezetimibe is. Often there is a workable adjustment short of stopping.
• If the indication has changed — for example a borderline-risk patient whose absolute risk has dropped after sustained lifestyle change — the question of whether to continue is reasonable to bring to the consult.
• Stopping cold turkey lets LDL return to its pre-treatment level over 2-4 weeks. If the indication was secondary prevention or familial hypercholesterolaemia, that loss of LDL control matters cardiovascularly.

Pregnancy and breastfeeding

Ezetimibe is not recommended in pregnancy. Safety data are limited. The AU and international convention is to pause ezetimibe (and any statin) when pregnancy is being planned, and to switch to lifestyle plus pregnancy-appropriate lipid management for the duration of pregnancy and breastfeeding.

• Planning a pregnancy: mention it before trying. There is usually time to plan the swap.
• Already on it and just found out you are pregnant: contact the prescribing GP as soon as possible. Pause the next dose until the conversation has happened.

Breastfeeding. Avoid; data on excretion into breast milk are limited.

The nuance. In secondary cardiovascular prevention where absolute risk is substantial — for example after a heart attack in a young patient, or in homozygous familial hypercholesterolaemia — the risk-benefit conversation is individualised with specialist input. Not a default; a specialist-supported exception.

If you are on a combination tablet

The two-drug combinations are common because they simplify the regimen and cost the same as a single PBS script.

• Atozet = atorvastatin + ezetimibe. Often used when atorvastatin alone has not reached target, or when adherence to two tablets has been a challenge.
• Vytorin / Inegy / Goltor = simvastatin + ezetimibe (the brand on the shelf has shifted over time — same drug, different labels). Taken at night because simvastatin is dosed nightly.

Everything on this page applies to the ezetimibe half of the tablet. The statin half has its own page (statins) with its own side-effect and interaction detail — especially the CYP3A4 interactions for atorvastatin and simvastatin. If a new medicine is being added by another doctor, mention the combination tablet by its full ingredient list so the interaction check is complete.

---

Where the next step is on the lipid-lowering ladder. If a statin plus ezetimibe is not enough, or not tolerated, the conversation moves to:

• Bempedoic acid (Nilemdo) — ATP-citrate lyase inhibitor, no muscle-symptom signal, supported by CLEAR Outcomes (NEJM 2023). AU availability has lagged the US and UK; confirm current ARTG / PBS status with the pharmacist.
• PCSK9 inhibitors — Praluent (alirocumab) and Repatha (evolocumab). Subcutaneous injections every 2 or 4 weeks. Reduce LDL by a further 50-60% on top of statin and ezetimibe. Supported by FOURIER (NEJM 2017) for evolocumab and ODYSSEY OUTCOMES (NEJM 2018) for alirocumab. PBS Streamlined Authority in Australia for very-high-cardiovascular-risk patients on a maximally-tolerated statin plus ezetimibe. Specialist-initiated; PBS eligibility criteria are periodically updated.

Cost

Ezetimibe is PBS-listed under Streamlined Authority. Eligibility requires LDL-C not at target on a maximally-tolerated statin, OR documented statin intolerance. The combination tablets (Atozet, Vytorin / Inegy / Goltor) are also PBS-listed. Confirm the current Streamlined Authority code and wording with the prescribing GP or pharmacist — the criteria are periodically updated.

From 1 January 2026, the PBS co-payment is:

• General patient: up to $25.00 per script
• Concession card holder: up to $7.70 per script

Generic ezetimibe is bioequivalent to Ezetrol and costs the same at PBS pricing. The combination tablets sit at the same PBS co-payment as a single script — one of the practical reasons they are useful. Confirm with the pharmacist — they can show the exact price for the script and the cheapest option.

---

The integrative view

Most patients on a cholesterol-lowering medicine want to do everything they reasonably can in addition to taking the tablet. This is the longer version of that conversation.

Two principles. First: ezetimibe (alone or with a statin) is a real lever and the trial evidence is established. Lifestyle change is also a real lever, with its own outcome evidence. The two stack — they do not substitute for each other for a patient with a clear clinical indication. Second: the integrative work happens alongside the medicine, not instead of it, and the conversation about reducing or stopping is one to have with the prescribing GP — together, with monitoring, not on your own.

Strong evidence — these reliably reduce cardiovascular events

These are the interventions with the strongest outcome evidence in cardiovascular prevention. Effect sizes here are described in terms of cardiovascular events rather than LDL change, because the events are what matter.

• Mediterranean-style eating (PREDIMED, NEJM 2018). Extra-virgin olive oil or mixed nuts as the fat backbone, vegetables, legumes, fish, modest red meat, modest dairy. Roughly 30% reduction in major cardiovascular events over 5 years, partly independent of LDL change. The strongest dietary evidence base for cardiovascular prevention.
• Regular aerobic and resistance exercise. 150 minutes per week of moderate aerobic activity plus 2-3 resistance sessions. Independent cardiovascular protection beyond lipid effects.
• Weight management for the patient who carries excess central adiposity. Improves the whole metabolic-syndrome cluster (insulin resistance, triglycerides, blood pressure, inflammatory markers).
• Smoking cessation. The single biggest modifiable cardiovascular risk reduction available, and it works fast — measurable risk reduction within the first year.

Moderate evidence — likely helpful

• Soluble fibre — psyllium husk (5-10 g per day) or oat beta-glucan (3 g per day). Lowers LDL by roughly 5-10% via bile-acid binding in the gut. Cheap, well-tolerated. Start low and build slowly to avoid bloating. Additive to ezetimibe and statins.
• Plant sterols and stanols — 2 g per day from fortified spreads, yoghurts, or capsules. Lowers LDL by a further 8-10% on top of a low-saturated-fat diet. Parallel mechanism to ezetimibe — both reduce cholesterol absorption, by different routes — and the effects are partly additive. Reasonable to stack.
• Omega-3 (prescription icosapent ethyl) — REDUCE-IT (NEJM 2019) showed icosapent ethyl 2 g twice daily reduced major cardiovascular events in patients with elevated triglycerides already on a statin. AU PBS availability for icosapent ethyl is limited. Over-the-counter mixed EPA/DHA fish oil does not carry the same outcome evidence.
• Alcohol moderation. AU NHMRC guidance is no more than 10 standard drinks per week and no more than 4 on any one day. Particularly relevant for the ezetimibe + statin combinations because the hepatic safety signal is additive.
• Sleep, in the patient with untreated sleep apnoea. Snoring plus daytime tiredness plus observed pauses in breathing is worth a sleep study. Untreated severe OSA worsens cardiovascular risk independently of lipids.

Limited or emerging evidence

• Berberine. Small-trial evidence for roughly 10-15% LDL reduction via upregulation of hepatic LDL receptors. AU evidence base is limited; supplement quality varies. A reasonable adjunct in selected patients, but not a substitute for evidence-based lipid lowering when there is a clear clinical indication.
• Red yeast rice. Contains monacolin K, chemically identical to lovastatin — so it is a low-dose statin in nature’s clothing. Do not combine with a prescribed statin and ezetimibe. Quality control between products is variable and citrinin contamination is a known concern. If chosen as the lipid-lowering agent instead of a prescribed statin, it should be monitored with the same blood tests (LFTs, CK, lipids).
• Garlic, hawthorn, niacin (nicotinic acid) at high dose. Mixed evidence for modest LDL change; no consistent cardiovascular outcome signal of the quality required for routine recommendation.

Specific to being on ezetimibe (alone or in combination)

• CoQ10 (ubiquinone). Ezetimibe on its own does not reduce CoQ10 — the mevalonate pathway is not blocked. The CoQ10 conversation is relevant only when ezetimibe is paired with a statin and unexplained muscle symptoms have arisen. In that setting, a pragmatic trial of 100-200 mg per day for 4-8 weeks is reasonable. Start at 100 mg with food, observe, adjust. Not a routine recommendation for asymptomatic patients.
• Vitamin D status. Low vitamin D is associated with worse muscle symptoms on lipid-lowering therapy. If new muscle symptoms develop on the statin combination, the 25-OH-D level is worth checking and supplementing to a target of 75-100 nmol/L.
• Magnesium-rich foods — leafy greens, nuts, seeds, legumes. Supports muscle function generally; no ezetimibe-specific evidence base, but a low-cost addition for a patient with muscle symptoms.

Earning a lower dose

If ezetimibe is on board as add-on therapy and genuine sustained lifestyle change has shifted the lipid profile and absolute cardiovascular risk meaningfully, the question of whether the add-on is still doing useful work is reasonable to bring to the prescribing GP. With monitoring — lipid panel, absolute-risk recalculation, home blood pressure — the regimen can sometimes be simplified.

Two caveats:

• This is a conversation with the prescribing GP, not a decision made alone.
• If ezetimibe is on board for secondary cardiovascular prevention, familial hypercholesterolaemia, post-acute coronary syndrome (per IMPROVE-IT), or chronic kidney disease (per SHARP), the evidence supports staying on the medicine regardless of what the LDL number does. The Mediterranean diet, regular exercise, weight management, alcohol moderation, and smoking cessation remain independent cardiovascular protectors worth doing anyway.

---

Track these between now and your next visit

• Any gastrointestinal symptoms — when they started, how often, how severe.
• Any muscle aches if a statin is on board (Atozet or Vytorin / Inegy / Goltor, or a separate statin) — when they started, what makes them better or worse.
• Anything new bought over the counter (painkillers, supplements, herbal products, salt substitutes).
• The lipid panel result if the GP has ordered one — bring it (or a printout) to the next visit.

Bring the list to the review appointment.

---

This is general information, not personal medical advice. Every patient is different. Decisions about your medicines — which one, what dose, when to stop, what to combine with — are made with the doctor who prescribed them. If anything on this page appears to contradict advice from your treating doctor, follow your doctor; they have context about your situation that this page cannot.

Reading this page does not establish a doctor-patient relationship with Dr Hoebing Lo. If you are not a current patient, please discuss your medicines with your own GP, specialist, or pharmacist.

About the integrative content. The lifestyle, dietary, and complementary recommendations on this page summarise current published research. Effect sizes are approximations from clinical studies — your individual response will vary, and real-world results are commonly smaller than trial results because day-to-day life differs from study conditions. Supplements and herbal products are not interchangeable with prescribed medication and can interact with it. Talk to your doctor and pharmacist before starting any new supplement, herbal product, or significant change in diet.

Currency. This page reflects clinical practice as of the last-reviewed date. Medicine evolves; specific details may date between reviews. Pricing shown is indicative; confirm with your pharmacist. PBS Streamlined Authority criteria for ezetimibe, the PCSK9 inhibitors, and the bempedoic acid listing have all been periodically updated — verify the current wording with the prescribing GP or pharmacist.

No commercial relationships. Dr Hoebing Lo has no financial or commercial relationship with the manufacturer of any medicine, brand, or supplement mentioned on this page.

Emergencies. If you have sudden swelling of face, lips, tongue, or throat; difficulty breathing; severe muscle pain with dark or tea-coloured urine; chest pain; or severe dizziness or fainting, call 000 or go to your nearest emergency department. Do not wait.